Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel JF, et al. Crohn's disease. Lancet. 2017;389(10080):1741–1755.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353.
   PubMed Web of Science ®Google Scholar
• Colombel JF, D'Haens G, Lee WJ, et al. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2020;14(2):254–266.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779–2789.
   PubMed Web of Science ®Google Scholar
• Singh S, Murad MH, Fumery M, et al. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18(10):2179–2191.e6.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919–927.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15(10):1580–1588.e3.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohns Colitis. 2018;12(7):804–810.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–1329 e3.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22(8):1999–2015.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Afif W, Drobne D, International Consortium for Therapeutic Drug Monitoring, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022;7(2):171–185.
   PubMed Web of Science ®Google Scholar
• Patel RN, Nigam GB, Jatale RG, et al. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. Indian J Gastroenterol. 2020;39(2):176–185.
   PubMed Web of Science ®Google Scholar
• Grossberg LB, Papamichael K, Feuerstein JD, et al. A survey study of gastroenterologists' attitudes and barriers Toward therapeutic drug monitoring of Anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(1):191–197.
   Web of Science ®Google Scholar
• Nigam GB, Patel RN, Jatale RG, et al. UK national survey of gastroenterologists’ attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Frontline Gastroenterology. 2020;158(6):S-246.
   Google Scholar
• Samaan MA, Arkir Z, Ahmad T, et al. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science? Expert Opin Biol Ther. 2018;18(12):1271–1279.
   PubMed Web of Science ®Google Scholar
• Thomas PWA, Chin PKL, Barclay ML. A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease. Intern Med J. 2021;51(3):341–347.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients With inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(9):1655–1668 e3.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Nguyen GC, Kupfer SS, American Gastroenterological Association Institute Clinical Guidelines Committee, et al. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–834.
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, IBD guidelines eDelphi consensus group, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Panaccione R, Targownik L, et al. Clinical practice guideline for the medical management of perianal fistulizing Crohn's disease: the Toronto consensus. Inflamm Bowel Dis. 2019;25(1):1–13.
   PubMed Web of Science ®Google Scholar
• Cheifetz AS, Abreu MT, Afif W, et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. Am J Gastroenterol. 2021;116(10):2014–2025.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Feagan BG, Wolf DC, et al. Therapeutic drug monitoring of tumor necrosis factor antagonists in crohn disease: a theoretical construct to apply pharmacokinetics and guidelines to clinical practice. Inflamm Bowel Dis. 2020;27(8):1346–1355.
   Web of Science ®Google Scholar
• Mitrev N, Vande Casteele N, Seow CH, IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11-12):1037–1053.
   PubMed Web of Science ®Google Scholar
• Sparrow MP, Papamichael K, Ward MG, et al. Therapeutic drug monitoring of biologics During induction to prevent primary Non-Response. J Crohns Colitis. 2020;14(4):542–556.
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
   PubMed Web of Science ®Google Scholar
• Syversen SW, Jørgensen KK, Goll GL, et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. Jama. 2021;326(23):2375–2384.
   PubMed Web of Science ®Google Scholar
• Fernandes SR, Bernardo S, Simoes C, et al. Proactive infliximab drug monitoring Is superior to conventional management in inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(2):263–270.
   PubMed Web of Science ®Google Scholar
• Sánchez-Hernández JG, Rebollo N, Martin-Suarez A, et al. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease. Br J Clin Pharmacol. 2020;86(6):1165–1175.
   PubMed Web of Science ®Google Scholar
• Coskun M, Steenholdt C, de Boer NK, et al. Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease. Clin Pharmacokinet. 2016;55(3):257–274.
   PubMed Web of Science ®Google Scholar
• Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: case series and review of literature. World J Gastrointest Pharmacol Ther. 2017;8(3):155–161.
   PubMedGoogle Scholar
• Syversen SW, Goll GL, Jørgensen KK, et al. Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021;325(17):1744–1754.
   PubMed Web of Science ®Google Scholar
• Van Stappen T, Bollen L, Vande Casteele N, et al. Rapid test for infliximab drug concentration allows immediate dose adaptation. Clin Transl Gastroenterol. 2016;7(12):e206.
   PubMed Web of Science ®Google Scholar
• Verstockt B, Moors G, Bian S, et al. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. Aliment Pharmacol Ther. 2018;48(7):731–739.
   PubMed Web of Science ®Google Scholar
• Hindorf U, Andersson P. How are thiopurines used and monitored by swedish gastroenterologists when treating patients with inflammatory bowel disease? Scand J Gastroenterol. 2011;46(10):1215–1221.
   PubMed Web of Science ®Google Scholar
• Cui G, Fan Q, Li Z, et al. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: current and novel biomarkers. EBioMedicine. 2021;66:103329.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44(7):774–781.
   PubMed Web of Science ®Google Scholar
• Gibson DJ, Ward MG, Rentsch C, et al. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51(6):612–628.
   PubMed Web of Science ®Google Scholar
• Shukla R, Ananthakrishnan A. Therapeutic drug monitoring of Non-Anti-Tumor necrosis factor biologics. Clin Gastroenterol Hepatol. 2021;19(6):1108–1110.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Herfarth H, Katz J, et al. American gastroenterological association institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153(3):835–857.e6.
   PubMed Web of Science ®Google Scholar